Hyperion Therapeutics Inc (HPTX) financial statements (2021 and earlier)

Company profile

Business Address 2000 SIERRA POINT PARKWAY
BRISBANE, CA 94005
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments13710250
Cash and cash equivalents1037450
Short-term investments3428 
Receivables154 
Inventory, net of allowances, customer advances and progress billings54
Inventory54 
Prepaid expense and other current assets1
Other undisclosed current assets31 
Total current assets:15911251
Noncurrent Assets
Property, plant and equipment110
Long-term investments and receivables916 
Long-term investments916 
Intangible assets, net (including goodwill)913
Intangible assets, net (excluding goodwill)913 
Other noncurrent assets21
Prepaid expense and other noncurrent assets0
Total noncurrent assets:21310
TOTAL ASSETS:18014351
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities35196
Accounts payable522
Accrued liabilities26123
Employee-related liabilities441
Taxes payable10 
Debt 64
Deferred revenue and credits0  
Other undisclosed current liabilities(5)(5)(1)
Total current liabilities:30209
Noncurrent Liabilities
Long-term debt and lease obligation1838
Long-term debt, excluding current maturities1838
Liabilities, other than long-term debt00 
Deferred revenue and credits00 
Total noncurrent liabilities:1838
Total liabilities:492317
Stockholders' equity
Stockholders' equity attributable to parent13212034
Common stock000
Additional paid in capital260242173
Accumulated other comprehensive loss(0)(0) 
Accumulated deficit(129)(122)(139)
Total stockholders' equity:13212034
TOTAL LIABILITIES AND EQUITY:18014351

Income statement (P&L) ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Revenues
(Revenue, Net)
11442 
Cost of revenue(14)(7) 
Gross profit:10035 
Operating expenses(118)(56)(29)
Other undisclosed operating income147 
Operating loss:(4)(13)(29)
Nonoperating income (expense)(0)1(0)
Investment income, nonoperating100
Other nonoperating income (expense)(1)1(0)
Interest and debt expense(1)(2)(4)
Loss from continuing operations before equity method investments, income taxes:(5)(14)(32)
Other undisclosed income (loss) from continuing operations before income taxes(1)31 
Income (loss) from continuing operations before income taxes:(6)17(32)
Income tax expense(0)(0) 
Net income (loss) available to common stockholders, diluted:(6)17(32)

Comprehensive Income ($ in millions)

12/31/2014
12/31/2013
12/31/2012
Net income (loss):(6)17(32)
Other comprehensive income (loss)0(0) 
Comprehensive income (loss), net of tax, attributable to parent:(6)17(32)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: